Abstract：Objective：To conduct a bibliometric analysis of the current status，research hotspots，and trends in pharmacological treatment for acute heart failure （AHF） over the past decade using tools such as VOSviewer and CiteSpace， thereby providing references for expanding future research directions and innovating treatment strategies. Methods： Literature on pharmacological treatment for AHF published between January 1， 2015 and December 31， 2024 was retrieved from the China National Knowledge Infrastructure （CNKI）， Wanfang Data Knowledge Service Platform （Wanfang），China Science and Technology Journal Database （VIP），and Web of Science. Knowledge graphs of pharmacological treatment for AHF were generated using VOSviewer and CiteSpace， and data analyses were performed on keywords， authors， and publishing institutions. Results： A total of 2 600 Chinese articles and 262 English articles were included，of which 447 articles focused on traditional Chinese medicine （TCM） pharmacological treatment and 2 415 articles on non-TCM pharmacological treatment. The overall number of publications showed a stable fluctuating trend. The institutions with the highest publication output were the 7th People's Hospital of Zhengzhou and the University of Groningen. Domestic authors and research teams in China contributed the majority of publications， exhibiting a "decentralized and fragmented" characteristic. Research on TCM pharmacological treatment for AHF primarily concentrated on etiology and pathogenesis theories， proven formulas from renowned physicians， classical prescriptions from ancient texts，Chinese patent medicines，and clinical indicators，forming a complete research chain of "syndrome differentiation- herbal prescription-multidimensional evaluation." In contrast， research related to non- TCM pharmacological treatment primarily emphasized clinical trials，exploration of pathological mechanisms，and the development of novel drugs. Conclusion： Future efforts should leverage the individualized advantages of TCM， characterized by "holistic concept and syndrome differentiation-based treatment， " and integrate them with the systematic therapeutic logic of non-TCM， which emphasizes "etiological control and precise target-oriented pharmacotherapy， " to establish an integrated treatment model. This approach aims to achieve early synergistic intervention for patients with AHF，to achieve a balance between enhanced efficacy and controlled adverse effects.